PMP22 and Charcot-Marie-Tooth disease type 1A: Although PXT3003 was shown to improve the symptoms of CMT1A in rats (56) and humans (60), its Pmp22-silencing efficiency was shown only at the mRNA level in the rat overexpressing murine Pmp22.